Ponatinib Polymorph Characterization for Manufacturing Consistency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of pharmaceuticals like ponatinib and ponatinib hydrochloride faces challenges due to the lack of understanding about their polymorphic forms, leading to inconsistent manufacturing and stability issues, which can affect drug performance.
Innovation Solution
The discovery and characterization of various crystalline and polymorphic forms of ponatinib and ponatinib hydrochloride, designated as Forms A to K, along with methods for their preparation and use in pharmaceutical formulations, ensuring stability and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polymorphic forms of ponatinib and ponatinib hydrochloride are not properly characterized, then manufacturing consistency and drug stability are compromised, but extensive polymorph screening and characterization increase development time and complexity
Solution Approach 1:
The patent applies preliminary action by conducting comprehensive polymorph screening and characterization during the early drug development phase. Multiple crystalline forms (Forms A-K) are identified and characterized before commercial manufacturing begins, establishing a knowledge base that enables consistent manufacturing later. This upfront investment in polymorph characterization prevents manufacturing inconsistencies.
Solution Approach 2:
The patent employs parameter changes by systematically varying crystallization conditions (solvents, temperatures, pH, additives) to discover and characterize different polymorphic forms. By understanding how these parameters affect polymorph formation, the patent establishes controlled manufacturing parameters that ensure reproducible production of the desired crystalline form with consistent drug performance.
2Stability of the object's composition
If polymorphic forms are not properly controlled, then drug stability and performance are affected, but rigorous polymorph control increases formulation development complexity
Solution Approach 1:
The patent uses parameter changes to identify and control the polymorphic form with optimal stability characteristics. By systematically evaluating different crystalline forms under various storage conditions, the patent selects the most stable polymorph and establishes formulation parameters (excipients, moisture control, packaging) that maintain this stability throughout the drug's shelf life.
Solution Approach 2:
The patent implements feedback mechanisms by establishing analytical methods to monitor polymorph form throughout the formulation development and manufacturing process. This includes using techniques like XRD and DSC to detect and quantify polymorphic forms, providing feedback that enables real-time control to ensure the desired stable form is maintained throughout production and storage.
3Manufacturing precision
If multiple polymorphic forms exist without proper identification, then manufacturing batches show variability, but comprehensive polymorph screening requires significant resources and time
Solution Approach 1:
The patent applies preliminary action by conducting exhaustive polymorph screening during the pre-commercial development phase. Forms A through K are identified and characterized before manufacturing processes are finalized, creating a reference framework that enables rapid batch-to-batch consistency. This upfront polymorph identification prevents manufacturing variability later.
Solution Approach 2:
The patent uses copying by creating detailed reference profiles for each identified polymorphic form, including their physical properties, stability characteristics, and formation conditions. These reference profiles serve as templates that enable manufacturers to replicate the desired polymorph form consistently across different batches by following established protocols and comparing results against the reference standards.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the reproducible preparation of stable, high-purity polymorphic forms of ponatinib and ponatinib hydrochloride, enhancing the consistency and efficacy of pharmaceutical formulations for treating conditions like chronic myeloid leukemia.
Implementation Method 1
The discovery and characterization of various crystalline and polymorphic forms of ponatinib and ponatinib hydrochloride, designated as Forms A to K
Data Source
AI summary
Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.